Cargando…

Single-dose ciraparantag safely and completely reverses anticoagulant effects of edoxaban

Of the new direct oral anticoagulants, direct factor Xa inhibitors are limited by the absence of a proven reversal agent. We assessed the safety, tolerability and impact on anticoagulation reversal of ciraparantag (PER977) alone and following a 60 mg dose of the FXa inhibitor edoxaban. Escalating, s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ansell, Jack E., Bakhru, Sasha H., Laulicht, Bryan E., Steiner, Solomon S., Grosso, Michael A., Brown, Karen, Dishy, Victor, Lanz, Hans J., Mercuri, Michele F., Noveck, Robert J., Costin, James C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Schattauer GmbH 2017
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6260118/ https://www.ncbi.nlm.nih.gov/pubmed/27853809 http://dx.doi.org/10.1160/TH16-03-0224

Ejemplares similares

Ciraparantag reverses the anticoagulant activity of apixaban and rivaroxaban in healthy elderly subjects
por: Ansell, Jack, et al.
Publicado: (2021)

Reversing anticoagulant effects of novel oral anticoagulants: role of ciraparantag, andexanet alfa, and idarucizumab
por: Hu, Tiffany Y, et al.
Publicado: (2016)

Sustained safe and effective anticoagulation using Edoxaban via percutaneous endoscopic gastrostomy
por: Galli, Mattia, et al.
Publicado: (2019)

Nonvitamin K antagonist oral anticoagulant activity: challenges in measurement and reversal
por: Brown, Karen S., et al.
Publicado: (2016)

Pharmacokinetics and Pharmacodynamics of the Nonvitamin K Antagonist Oral Anticoagulant Edoxaban When Administered Alone or After Switching from Rivaroxaban or Dabigatran Etexilate in Healthy Subjects
por: Parasrampuria, Dolly A., et al.
Publicado: (2015)

Andexanet Alfa for Specific Anticoagulation Reversal in Patients with Acute Bleeding during Treatment with Edoxaban
por: Benz, Alexander P., et al.
Publicado: (2022)

Magnetic resonance venography to assess thrombus resolution with edoxaban monotherapy versus parenteral anticoagulation/warfarin for symptomatic deep vein thrombosis: A multicenter feasibility study
por: Piazza, Gregory, et al.
Publicado: (2016)

Reversal of edoxaban-induced anticoagulation by the four-factor prothrombin complex concentrate Beriplex(® )in a rabbit model
por: Herzog, E, et al.
Publicado: (2014)

Genetics and clinical response to warfarin and edoxaban in patients with venous thromboembolism
por: Vandell, Alexander G, et al.
Publicado: (2017)

Andexanet alfa effectively reverses edoxaban anticoagulation effects and associated bleeding in a rabbit acute hemorrhage model
por: Lu, Genmin, et al.
Publicado: (2018)

Periprocedural anticoagulation in the uninterrupted edoxaban vs. vitamin K antagonists for ablation of atrial fibrillation (ELIMINATE-AF) trial
por: Hohnloser, Stefan H, et al.
Publicado: (2020)

Edoxaban Exposure in Patients With Atrial Fibrillation and Estimated Creatinine Clearance Exceeding 100 mL/min
por: Yin, Ophelia, et al.
Publicado: (2021)

Pharmacokinetics of anticoagulant edoxaban in overdose in a Japanese patient transported to hospital
por: Adachi, Koichiro, et al.
Publicado: (2020)

Efficacy and Safety of Edoxaban in Elderly Patients With Atrial Fibrillation in the ENGAGE AF–TIMI 48 Trial
por: Kato, Eri Toda, et al.
Publicado: (2016)

Cost-Effectiveness of Anticoagulation in Patients with Nonvalvular Atrial Fibrillation with Edoxaban Compared to Warfarin in Germany
por: Krejczy, Martin, et al.
Publicado: (2015)

The Edoxaban Hokusai VTE PEDIATRICS Study: An open‐label, multicenter, randomized study of edoxaban for pediatric venous thromboembolic disease
por: van Ommen, Cornelia Heleen, et al.
Publicado: (2020)

Management of venous thromboembolism: clinical guidance from the Anticoagulation Forum
por: Ansell, Jack E.
Publicado: (2016)

Drug-Drug Interaction Studies of Cardiovascular Drugs Involving P-Glycoprotein, an Efflux Transporter, on the Pharmacokinetics of Edoxaban, an Oral Factor Xa Inhibitor
por: Mendell, Jeanne, et al.
Publicado: (2013)

Pharmacokinetics and Pharmacodynamics of Edoxaban, a Non-Vitamin K Antagonist Oral Anticoagulant that Inhibits Clotting Factor Xa
por: Parasrampuria, Dolly A., et al.
Publicado: (2015)

Anticoagulation treatment and prophylactic edoxaban for cerebral sinus venous thrombosis in an adolescent with acute lymphoblastic leukemia
por: Koganesawa, Masaya, et al.
Publicado: (2021)

Target-Specific Oral Anticoagulants—New Approaches in the Field of Oral Anticoagulation
por: Mani, Helen, et al.
Publicado: (2015)

The edoxaban‐M4 metabolite and measurement of edoxaban by chromogenic assays in human plasma
por: Siriez, Romain, et al.
Publicado: (2022)

Point-of-care testing for emergency assessment of coagulation in patients treated with direct oral anticoagulants including edoxaban
por: Härtig, Florian, et al.
Publicado: (2021)

Edoxaban Vs. Low Molecular Weight Heparin As Anticoagulant Therapy in Hospitalized Patients with Atrial Fibrillation and COVID-19 Infection
por: Olivera, Pável E, et al.
Publicado: (2020)

Outpatient Management in Patients with Venous Thromboembolism with Edoxaban: A Post Hoc Analysis of the Hokusai-VTE Study
por: Medina, Andria, et al.
Publicado: (2017)

Deep Vein Thrombosis in Severe Motor and Intellectual Disabilities Patients and Its Treatment by Anticoagulants of Warfarin Versus Edoxaban
por: Ohmori, Hiromitsu, et al.
Publicado: (2019)

Effect of edoxaban compared with other oral anticoagulants for stroke prevention in patients with atrial fibrillation: A meta-analysis
por: Zhang, Bailin, et al.
Publicado: (2023)

Stroke Prevention in Atrial Fibrillation in the Very Elderly: Anticoagulant Therapy Is No Longer a Sin
por: Ansell, Jack
Publicado: (2017)

Edoxaban in the Evolving Scenario of Non Vitamin K Antagonist Oral Anticoagulants Imputed Placebo Analysis and Multiple Treatment Comparisons
por: Verdecchia, Paolo, et al.
Publicado: (2014)

Risk factors for gastrointestinal bleeding in patients with gastrointestinal cancer using edoxaban
por: Bosch, Floris T. M., et al.
Publicado: (2021)

Managing patients taking edoxaban in dentistry
por: Curto, Adrian, et al.
Publicado: (2017)

Edoxaban: Minor bleeding: case report
Publicado: (2022)

Protocol for LASER: A Randomized Evaluation and an Associated Registry of Early Anticoagulation With Edoxaban After Ischemic Stroke in Patients With Atrial Fibrillation
por: Alrohimi, Anas, et al.
Publicado: (2021)

Hokusai-VTE: Edoxaban for the treatment of venous thromboembolism
por: Said, Karim
Publicado: (2013)

The Effect of Rifampin on the Pharmacokinetics of Edoxaban in Healthy Adults
por: Mendell, Jeanne, et al.
Publicado: (2015)

Edoxaban in venous thromboembolism and stroke prevention: an appraisal
por: Proietti, Marco, et al.
Publicado: (2016)

Diffuse Alveolar Hemorrhage Associated with Edoxaban Therapy
por: Nitta, Kenichi, et al.
Publicado: (2016)

Superior mesenteric vein thrombosis treated with edoxaban
por: Hashizume, Yutaka, et al.
Publicado: (2017)

Impact of Edoxaban on Thrombin-Dependent Platelet Aggregation
por: Sokol, Juraj, et al.
Publicado: (2020)

Use of Edoxaban for the Treatment of Heparin-Induced Thrombocytopenia
por: Kanamoto, Ryo, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_pc9tfh6se8ttl5dncajlpce99k